P1, N=10, Active, not recruiting, University Hospital, Basel, Switzerland | Trial completion date: Jun 2025 --> Jun 2026 | Recruiting --> Active, not recruiting

13 days ago

Enrollment closed • Trial completion date

BRAF (B-raf proto-oncogene)

BRAF mutation • BRAF V600

ANV419

14d

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2027 --> Oct 2029 | Trial primary completion date: Oct 2027 --> Oct 2029

14 days ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab) • Starasid (cytarabine ocfosfate)

16d

EBV INFECTION OUTCOMES DETERMINED BY MONOCYTE AND T REG -DRIVEN IMMUNE DYNAMICS IN AN EX VIVO PBMC MODEL. (PubMed, bioRxiv)

Treatment with the Treg-depleting antibody RG6292 suppressed viral transformation in donors that otherwise supported LCL outgrowth, confirming a functional role for Tregs in shaping early EBV infection outcomes. Viral transcript enrichment-seq revealed an upregulation of early lytic and failure to sustain latent gene expression correlating with failure to generate LCL. These findings highlight intact PBMCs as a tractable model to study EBV viral-host interaction in a genetically diverse, human-specific context, and that Tregs play a key determining role in viral transformation.

16 days ago

Preclinical • Journal

CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • CCR2 (C-C Motif Chemokine Receptor 2)

vopikitug (RG6292)

Comparative Oncology: Cross-Sectional Single-Cell Transcriptomic Profiling of the Tumor Microenvironment Across Seven Human Cancers. (PubMed, Cancers (Basel))

The competitive receptor ACKR1 was minimally expressed on endothelial cells, consistent with PDAC hypo-vascularity...Differential interactions and the presence of "dominant signaling cell populations " with dominant outgoing signals may underlie the heterogeneity in tumor aggressiveness across these cancers. Comparative scRNA-seq analysis of multiple cancers reveals distinct tumor phenotypes and cell-cell communication patterns, offering insights into the molecular architecture of human solid tumors.

1 month ago

Journal

IGF1 (Insulin-like growth factor 1) • EPCAM (Epithelial cell adhesion molecule) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • ACKR1 (Atypical Chemokine Receptor 1)

Zinbryta (daclizumab)

SIMPLE: Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (clinicaltrials.gov)

P4, N=20, Terminated, University of Southern California | N=80 --> 20 | Recruiting --> Terminated; Research contract expired

1 month ago

Enrollment change • Trial termination

prednisone • Simulect (basiliximab)

Stem Cell Transplantation for Patients With Multiple Myeloma (clinicaltrials.gov)

P1, N=30, Completed, University of Chicago | Active, not recruiting --> Completed | N=15 --> 30

1 month ago

Trial completion • Enrollment change

melphalan • Simulect (basiliximab) • plerixafor

2ms

Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation. (PubMed, Transpl Int)

These results were maintained even after IPTW adjustment. In SPKT recipients with low immunological risk, basiliximab provides comparable long-term patient and graft outcomes to thymoglobulin while reducing the incidence of opportunistic infections.

2 months ago

Retrospective data • Journal

IL2 (Interleukin 2)

Simulect (basiliximab)

3ms

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)

P1/2, N=159, Recruiting, Aulos Bioscience, Inc. | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

3 months ago

Trial completion date • Trial primary completion date • First-in-human

Opdivo (nivolumab) • Bavencio (avelumab) • Proleukin (aldesleukin) • imneskibart (AU-007)

3ms

ONSET: 1 vs 7 RATG Infusions in Renal Transplantation (clinicaltrials.gov)

P=N/A, N=75, Active, not recruiting, Mario Negri Institute for Pharmacological Research | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

Simulect (basiliximab)

4ms

Induction Therapy with ATLG in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation Following Preoperative Immune Checkpoint Inhibitor Treatment: A Prospective, Multicenter, Randomized Controlled Trial (ChiCTR2500106702)

P=N/A, N=220, Not yet recruiting, Huashan hospital affiliated to Fudan university; Huashan hospital affiliated to Fudan university

4 months ago

New trial • Checkpoint inhibition

PD-L1 (Programmed death ligand 1)

Simulect (basiliximab)

5ms

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)

P1, N=7, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=12 --> 7

5 months ago

Enrollment closed • Enrollment change

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)

IL2RA expression

melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)